Bio-Technology General
Mountain View Pharmaceuticals
Mountain View Pharmaceuticals (Menlo Park, CA) and Bio-Technology General (acquired by Savient Pharmaceuticals) (Israel), were funded by the BIRD Foundation to develop KRYSTEXXA™
a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients that are refractory to conventional therapy. On September 15, 2010, KRYSTEXXA™ was approved by the U.S. Food and Drug Administration (FDA).
Approved June 1988
